Literature DB >> 10963674

Virus neutralization by germ-line vs. hypermutated antibodies.

U Kalinke1, A Oxenius, C Lopez-Macias, R M Zinkernagel, H Hengartner.   

Abstract

Mice infected with vesicular stomatitis virus (VSV), a cytopathic virus closely related to rabies virus, mount a virus-neutralizing antibody response protecting against lethal disease. VSVneutralizing monoclonal IgGs isolated from primary immune responses were devoid of somatic mutations, whereas most secondary and all hyperimmune response IgGs tested were hypermutated. A comparative analysis of recombinant single-chain antibody fragments (scFv-Ckappa) revealed that even the germ-line precursor of one hypermutated antibody bound and neutralized VSV. Four somatic amino acid substitutions in V(H) increased by 300-fold the binding strength of monovalent scFv-Ckappa. The multivalent binding avidity of germ-line scFv-Ckappa was increased by more than 10-fold compared with the monovalent binding strength. In contrast, hypermutated scFv-Ckappa did not show such avidity effects. Thus the overall binding difference between the germ-line and the hypermutated VSV-neutralizing antibody was only 10- to 15-fold. This may explain why primary germ-line antibodies and secondary hypermutated antibodies directed against pathogens such as viruses and bacteria expressing repetitive antibody determinants show rather similar binding qualities, whereas monovalently binding hapten-specific antibodies can show "affinity maturation" effects of up to 1000-fold.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10963674      PMCID: PMC27744          DOI: 10.1073/pnas.97.18.10126

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  36 in total

Review 1.  The role of germinal centers for antiviral B cell responses.

Authors:  M F Bachmann
Journal:  Immunol Res       Date:  1998       Impact factor: 2.829

2.  The role of antibody concentration and avidity in antiviral protection.

Authors:  M F Bachmann; U Kalinke; A Althage; G Freer; C Burkhart; H Roost; M Aguet; H Hengartner; R M Zinkernagel
Journal:  Science       Date:  1997-06-27       Impact factor: 47.728

3.  Mapping of the dominant neutralizing antigenic site of a virus using infected cells.

Authors:  H P Roost; A Haag; C Burkhart; R M Zinkernagel; H Hengartner
Journal:  J Immunol Methods       Date:  1996-02-05       Impact factor: 2.303

4.  Early high-affinity neutralizing anti-viral IgG responses without further overall improvements of affinity.

Authors:  H P Roost; M F Bachmann; A Haag; U Kalinke; V Pliska; H Hengartner; R M Zinkernagel
Journal:  Proc Natl Acad Sci U S A       Date:  1995-02-28       Impact factor: 11.205

5.  A pulmonary influenza virus infection in SCID mice can be cured by treatment with hemagglutinin-specific antibodies that display very low virus-neutralizing activity in vitro.

Authors:  K Mozdzanowska; M Furchner; G Washko; J Mozdzanowski; W Gerhard
Journal:  J Virol       Date:  1997-06       Impact factor: 5.103

6.  The role of somatic mutation in the generation of the protective humoral immune response against vesicular stomatitis virus.

Authors:  U Kalinke; E M Bucher; B Ernst; A Oxenius; H P Roost; S Geley; R Kofler; R M Zinkernagel; H Hengartner
Journal:  Immunity       Date:  1996-12       Impact factor: 31.745

7.  Monovalent single-chain Fv fragments and bivalent miniantibodies bound to vesicular stomatitis virus protect against lethal infection.

Authors:  U Kalinke; A Krebber; C Krebber; E Bucher; A Plückthun; R M Zinkernagel; H Hengartner
Journal:  Eur J Immunol       Date:  1996-12       Impact factor: 5.532

8.  Mathematical model of a virus-neutralizing immunglobulin response.

Authors:  G A Funk; A D Barbour; H Hengartner; U Kalinke
Journal:  J Theor Biol       Date:  1998-11-07       Impact factor: 2.691

9.  Antiviral protection by vesicular stomatitis virus-specific antibodies in alpha/beta interferon receptor-deficient mice.

Authors:  U Steinhoff; U Müller; A Schertler; H Hengartner; M Aguet; R M Zinkernagel
Journal:  J Virol       Date:  1995-04       Impact factor: 5.103

10.  The mammalian cell-virus relationship. I. Attachment of poliovirus to cultivated cells of primate and non-primate origin.

Authors:  L C McLAREN; J J HOLLAND; J T SYVERTON
Journal:  J Exp Med       Date:  1959-05-01       Impact factor: 14.307

View more
  15 in total

1.  MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines.

Authors:  Surender Khurana; Nitin Verma; Jonathan W Yewdell; Anne Katrin Hilbert; Flora Castellino; Maria Lattanzi; Giuseppe Del Giudice; Rino Rappuoli; Hana Golding
Journal:  Sci Transl Med       Date:  2011-06-01       Impact factor: 17.956

2.  Construction and functional activities of chimeric mouse-human immunoglobulin G and immunoglobulin M antibodies against the Neisseria meningitidis PorA P1.7 and P1.16 epitopes.

Authors:  Terje E Michaelsen; Øistein Ihle; Karen Johanne Beckstrøm; Tove K Herstad; Jan Kolberg; E Arne Høiby; Audun Aase
Journal:  Infect Immun       Date:  2003-10       Impact factor: 3.441

3.  Polyreactive antigen-binding B (PAB-) cells are widely distributed and the PAB population consists of both B-1+ and B-1- phenotypes.

Authors:  Z-H Zhou; A L Notkins
Journal:  Clin Exp Immunol       Date:  2004-07       Impact factor: 4.330

4.  Molecular features of the broadly neutralizing immunoglobulin G1 b12 required for recognition of human immunodeficiency virus type 1 gp120.

Authors:  Michael B Zwick; Paul W H I Parren; Erica O Saphire; Sarah Church; Meng Wang; Jamie K Scott; Philip E Dawson; Ian A Wilson; Dennis R Burton
Journal:  J Virol       Date:  2003-05       Impact factor: 5.103

5.  Combinatorial antibody libraries from survivors of the Turkish H5N1 avian influenza outbreak reveal virus neutralization strategies.

Authors:  Arun K Kashyap; John Steel; Ahmet F Oner; Michael A Dillon; Ryann E Swale; Katherine M Wall; Kimberly J Perry; Aleksandr Faynboym; Mahmut Ilhan; Michael Horowitz; Lawrence Horowitz; Peter Palese; Ramesh R Bhatt; Richard A Lerner
Journal:  Proc Natl Acad Sci U S A       Date:  2008-04-14       Impact factor: 11.205

6.  Specificity and diversity of antibodies to Mycobacterium tuberculosis arabinomannan.

Authors:  Josephine Anne D Navoa; Suman Laal; Liise-Anne Pirofski; Gary R McLean; Zhongdong Dai; John B Robbins; Rachel Schneerson; Arturo Casadevall; Aharona Glatman-Freedman
Journal:  Clin Diagn Lab Immunol       Date:  2003-01

Review 7.  How specific is too specific? B-cell responses to viral infections reveal the importance of breadth over depth.

Authors:  Nicole Baumgarth
Journal:  Immunol Rev       Date:  2013-09       Impact factor: 12.988

8.  Potent germline-like monoclonal antibodies: rapid identification of promising candidates for antibody-based antiviral therapy.

Authors:  Xiaoyi Zhu; Fei Yu; Yanling Wu; Tianlei Ying
Journal:  Antib Ther       Date:  2021-05-17

9.  Maturation Pathways of Cross-Reactive HIV-1 Neutralizing Antibodies.

Authors:  Xiaodong Xiao; Weizao Chen; Yang Feng; Dimiter S Dimitrov
Journal:  Viruses       Date:  2009-11-06       Impact factor: 5.048

10.  Use of molecular modeling and site-directed mutagenesis to define the structural basis for the immune response to carbohydrate xenoantigens.

Authors:  Mary Kearns-Jonker; Natasha Barteneva; Robert Mencel; Namath Hussain; Irina Shulkin; Alan Xu; Margaret Yew; Donald V Cramer
Journal:  BMC Immunol       Date:  2007-03-12       Impact factor: 3.615

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.